Literature DB >> 30298359

Functional evaluation of alternative splicing in the FAM190A gene.

Sung Ung Kang1, Joon Tae Park2.   

Abstract

The human FAM190A gene undergoes frequent alteration in human cancer, most commonly involving in-frame deletions in exon 9 or exons 9 & 10. These deletions form novel peptide sequences, serving as presumptive cancer-specific neo antigens. However, it remains elusive whether these in-frame deletions of FAM190A could induce oncogenic properties in vivo. In this study, we aimed to explore the functional significance of in-frame deletions in FAM190A genes. We generated two deletion mutant forms, FAM190AΔexon9 and FAM190AΔexon9&10, and examined their gain-of-function effects in vitro and in vivo. Global transcript profiling in NIH3T3 cells revealed that the transcripts displaying altered expression following introduction of FAM190AΔexon9 and FAM190AΔexon9&10 were significantly enriched for genes assigned to cellular movement and cell-to-cell signaling, respectively. Furthermore, ectopic expression of FAM190AΔexon9 and FAM190AΔexon9&10 induced in vivo tumor formation in nu/nu mice. Taken together, our results are the first to demonstrate the in vivo oncogenic properties of in-frame deletions in the FAM190A gene and indicate that these transcript variants might be clinically applicable as therapeutic targets in patients with cancer.

Entities:  

Keywords:  Alternative splicing; FAM190A; Gain-of-function; Neo antigens; Xenograft

Mesh:

Substances:

Year:  2018        PMID: 30298359     DOI: 10.1007/s13258-018-0752-7

Source DB:  PubMed          Journal:  Genes Genomics        ISSN: 1976-9571            Impact factor:   1.839


  21 in total

1.  Abnormally spliced beta-globin mRNAs: a single point mutation generates transcripts sensitive and insensitive to nonsense-mediated mRNA decay.

Authors:  Sven Danckwardt; Gabriele Neu-Yilik; Rolf Thermann; Ute Frede; Matthias W Hentze; Andreas E Kulozik
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

Review 2.  Alternative pre-mRNA splicing and proteome expansion in metazoans.

Authors:  Tom Maniatis; Bosiljka Tasic
Journal:  Nature       Date:  2002-07-11       Impact factor: 49.962

Review 3.  Aberrant RNA splicing and its functional consequences in cancer cells.

Authors:  James D Fackenthal; Lucy A Godley
Journal:  Dis Model Mech       Date:  2008 Jul-Aug       Impact factor: 5.758

Review 4.  DNA damage, aging, and cancer.

Authors:  Jan H J Hoeijmakers
Journal:  N Engl J Med       Date:  2009-10-08       Impact factor: 91.245

Review 5.  Aberrant and alternative splicing in cancer.

Authors:  Julian P Venables
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

6.  Exon-level transcriptome profiling in murine breast cancer reveals splicing changes specific to tumors with different metastatic abilities.

Authors:  Amandine Bemmo; Christel Dias; April A N Rose; Caterina Russo; Peter Siegel; Jacek Majewski
Journal:  PLoS One       Date:  2010-08-06       Impact factor: 3.240

7.  FAM190A rearrangements provide a multitude of individualized tumor signatures and neo-antigens in cancer.

Authors:  Francesca Scrimieri; Eric S Calhoun; Kalpesh Patel; Rigu Gupta; David L Huso; Ralph H Hruban; Scott E Kern
Journal:  Oncotarget       Date:  2011 Jan-Feb

8.  Expression of tumour-specific antigens underlies cancer immunoediting.

Authors:  Michel DuPage; Claire Mazumdar; Leah M Schmidt; Ann F Cheung; Tyler Jacks
Journal:  Nature       Date:  2012-02-08       Impact factor: 49.962

9.  Chemotherapy and dietary phytochemical agents.

Authors:  Katrin Sak
Journal:  Chemother Res Pract       Date:  2012-12-20

Review 10.  Oncogenic alternative splicing switches: role in cancer progression and prospects for therapy.

Authors:  Serena Bonomi; Stefania Gallo; Morena Catillo; Daniela Pignataro; Giuseppe Biamonti; Claudia Ghigna
Journal:  Int J Cell Biol       Date:  2013-10-27
View more
  2 in total

1.  Interplay between Genome, Metabolome and Microbiome in Colorectal Cancer.

Authors:  Koldo Garcia-Etxebarria; Marc Clos-Garcia; Oiana Telleria; Beatriz Nafría; Cristina Alonso; Marta Iruarrizaga-Lejarreta; Andre Franke; Anais Crespo; Agueda Iglesias; Joaquín Cubiella; Luis Bujanda; Juan Manuel Falcón-Pérez
Journal:  Cancers (Basel)       Date:  2021-12-10       Impact factor: 6.639

2.  Deletion of a pseudogene within a fragile site triggers the oncogenic expression of the mitotic CCSER1 gene.

Authors:  Benedetta M Santoliquido; Michela Frenquelli; Claudia Contadini; Stefano Bestetti; Marco Gaviraghi; Elisa Barbieri; Anna De Antoni; Luca Albarello; Angelo Amabile; Alessandro Gardini; Angelo Lombardo; Claudio Doglioni; Paolo Provero; Silvia Soddu; Davide Cittaro; Giovanni Tonon
Journal:  Life Sci Alliance       Date:  2021-06-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.